Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Long-term survival of uveal melanoma patients after surgery for liver metastases

(2009) S Frenkel et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

(2009) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

9315 Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy

(2009) R. Danielli et al.   EJC SUPPLEMENTS

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

Survival in Patients With Uveal Melanoma in Europe

(2008) Gianni Virgili   ARCHIVES OF OPHTHALMOLOGY